FDA Adverse Event Death Summary report: N

RESOLUTE ONYX RX

MDR report key: 7600248 · Received June 14, 2018

Report

Report Number
9612164-2018-01446
Event Type
Death
Date Received
June 14, 2018
Date of Event
May 8, 2018
Report Date
June 14, 2018
Manufacturer
MEDTRONIC IRELAND
Product Code
NIQ
PMA / PMN Number
P160043
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
KS
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

JOURNAL NAME: CARDIOLOGY JOURNAL YEAR: 2018 AUTHORS: YONGCHEOL KIM, SUNG SIK OH, MYUNG HO JEONG, YOUNGKEUN AHN, JU HAN KIM, YOUNG JOON HONG, DOO SUN SIM, MIN CHUL KIM, HYO-SOO KIM, KYEONG HO YUN, SEOK KYU OH, CHONG JIN KIM, MYEONG CHAN CHO TITLE OF ARTICLE: COMPARISON OF SHORT-TERM CLINICAL OUTCOMES BETWEEN RESOLUTE ONYX ZOTAROLIMUS-ELUTING STENTS AND EVEROLIMUS-ELUTING STENT IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: RESULTS FROM THE KOREA ACUTE MYOCARDIAL INFARCTION REGISTRY (KAMIR). IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

THE STUDY COMPARED THE CLINICAL OUTCOMES OF MEDTRONIC RESOLUTE ONYX ZOTAROLIMUS-ELUTING STENT (O-ZES) AND NON-MEDTRONIC EVEROLIMUS-ELUTING STENTS (EES) IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING SUCCESSFUL PERCUTANEOUS CORONARY INTERVENTION (PCI). RESOLUTE ONYX DRUG-ELUTING STENTS WERE IMPLANTED IN 402 PATIENTS IN THE STUDY POPULATION. THE PRIMARY ENDPOINT WAS TARGET-LESION FAILURE DEFINED AS COMPOSITE OF CARDIAC DEATH, TARGET-VESSEL MYOCARDIAL INFARCTION AND ISCHEMIC-DRIVEN TARGET LESION REVASCULARIZATION. PATIENTS WERE ON DAPT. VESSELS TREATED WERE LAD, LCX, RCA AND LEFT MAIN. AT 6-MONTHS FOLLOW-UP CLINICAL OUTCOMES REPORTED WERE CARDIAC DEATH, TARGET-VESSLE MYOCARDIAL INFARCTION AND STENT THROMBOSIS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
443272 RESOLUTE ONYX RX STENT, CORONARY, DRUG-ELUTING NIQ MEDTRONIC IRELAND

Patients

Seq Age Sex Outcome Treatment
1 64 YR Death